The diagnosis of syphilis is often based on the results of serology using assays designed to detect either nontreponemal (e.g., rapid plasma reagin [RPR]) or treponema-specific antibodies (e.g., fluorescent treponemal antibody [FTA] ). Historically, serum samples have been screened using a nontreponemal test, with positive samples being confirmed by a treponemal assay (5) . While this approach is cost effective and demonstrates reliable performance in areas of high disease prevalence, it has several limitations, including low test throughput and the subjective interpretation of nontreponemal screening results. Recently, the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL) released an updated algorithm for laboratory testing and result interpretation of samples from patients with suspected Treponema pallidum infection (1) . This algorithm suggests that in areas of low disease prevalence (e.g., a rate of Ͻ2.2 per 100,000 population; http://www.cdc.gov/std/stats09 /figures/37.htm), samples may be screened using a treponemaspecific assay (e.g., enzyme immunoassay [EIA]), with positive samples being analyzed with a nontreponemal test to assess disease and treatment status.
Treponemal assays based on EIA, chemiluminescence immunoassay (CIA), or multiplex flow immunoassay (MFI) technology are often chosen for screening over conventional methods, such as FTA or Treponema pallidum particle agglutination (TP-PA) assay, due to higher testing throughput and the objective interpretation of results. However, the use of a treponemal test (whether it is a conventional or contemporary method) for screening purposes is not without limitations. With the increasing implementation of treponema-specific assays as first-line syphilis screening tests, health care providers are now faced with patients who are positive by a treponemaspecific screening test yet are negative by nontreponemal tests (10) . This discordance in test results is commonly observed in our laboratory and is the source of much confusion and anxiety among health care providers and patients. Although such result discordance may suggest a false-positive screening test, it may also occur in patients with past or recently treated syphilis and in patients with very early or late/latent disease (8) . Given these variables in interpretation, health care providers must perform careful reviews of their patients' disease and treatment histories. If a false-positive screening test is suspected based on a low pretest probability of disease, a second treponema-specific test (e.g., FTA) is recommended before ruling out the diagnosis of syphilis. Similarly, if such result discordance is observed in a patient without a history of treatment, a second treponema-specific test should be performed to rule out early or late/latent disease (1) . 
MATERIALS AND METHODS
Study design. Serum samples (n ϭ 303) submitted to our reference laboratory were tested with the 7 treponema-specific assays described below. In addition, each sample was tested with an RPR and an IgM WB assay (Viramed Treponema ViraBlot) to assess potential recent infection. Among the 303 serum samples, 203 (67.0%) were submitted consecutively from hospitals and clinics throughout the United States, while the remaining 100 (33.0%) samples were selected based on the results of prior syphilis testing in our laboratory. Samples were collected and tested over the study period (ϳ60 days), with technologists blinded to the results of other tests. Samples were stored at 4°C until all testing was complete so that analyses were performed in the same freeze-thaw cycle. The study protocol was reviewed by the institutional review board at our center.
Enzyme immunoassay. All serum samples were tested according to the manufacturer's instructions using the following EIAs Fluorescent treponemal antibody absorption. Testing using the FTA assay (Zeus Scientific) was performed according to the manufacturer's instructions. The Zeus FTA assay employs nonviable T. pallidum (Nichols strain) as the substrate capture antigen for the detection of total antibodies against T. pallidum.
Multiplex flow immunoassay. Testing by MFI was performed according to the manufacturer's instructions, using the BioPlex 2200 syphilis IgG kit on a BioPlex 2200 analyzer (3). The BioPlex syphilis IgG kit consists of three different populations of dyed beads that are coated with recombinant proteins derived from T. pallidum (Tp15, Tp17, and Tp47). Following flow cytometric analysis, the data are initially calculated in relative fluorescence intensity (RFI) and are then converted to a fluorescence ratio (FR) using an internal standard bead. The FR is compared to an assay-specific calibration curve to determine analyte concentration in antibody index (AI) units. The interpretive criteria were established by the manufacturer, and results are defined as negative (Յ0.8 AI), equivocal (0.9 to 1.0 AI), or positive (Ն1.1 AI).
Rapid plasma reagin assay. Testing by the RPR assay was performed according to the manufacturer's instructions using the BD Macro-Vue assay (Becton Dickinson, Franklin Lakes, NJ). Serum samples were tested undiluted, and in addition, a 2-fold dilution series was prepared using 0.9% sodium chloride diluent as outlined in the manufacturer's instructions.
Treponema pallidum particle agglutination. Samples were tested with the Serodia TP-PA assay (Fujirebio, Inc.) according to the manufacturer's instructions. This assay is based on the agglutination of colored gelatin particles that have been sensitized (coated) with T. pallidum (Nichols strain) antigen. Testing and result interpretation were performed in strict accordance with the recommendations outlined in the manufacturer's instructions.
Western blot analysis for IgG and IgM class antibodies. Testing by WB was performed according to the manufacturer's instructions using the Treponema ViraBlot IgG and IgM assays (Viramed Biotech AG). These assays utilize nitrocellulose strips with T. pallidum-specific antigens Tp47, Tp44.5, Tp17, and Tp15. Sample processing was performed using a BeeBlot (BeeRobotics, Gwynedd, United Kingdom). Test strips were then scanned and analyzed using the ViraScan interpretive software (Viramed Biotech AG), with the final interpretation of results being made by a laboratory technologist.
Assessment of analytical specificity. In order to assess the analytical specificity of the evaluated treponemal assays, sera known to be positive for potentially cross-reactive analytes (anti-herpes simplex virus IgM were tested with each treponema-specific assay and the RPR assay. In addition, sera collected from pregnant females (n ϭ 28) for routine prenatal serology were tested.
Analysis of turnaround time, sample throughput, and cost. The approximate turnaround time (TAT) for testing and reporting of 100 serum samples for each treponema-specific assay was calculated using incubation and reaction times provided in the manufacturer's instructions for use. Estimations were made based on the use of a single instrument or performing technologist. The sample throughput of each assay was then calculated for a 9-h shift using the following equation: (9/TAT) ϫ 100. The cost-per-patient for each treponema-specific test was determined as the list price for reagents, as supplied by the manufacturer, and does not account for instrumentation or personnel cost associated with testing.
Statistics. Statistical analyses were performed using GraphPad software (GraphPad Software, Inc.; http://graphpad.com/quickcalcs/index.cfm). In addition to percent agreement, kappa coefficients were calculated as a secondary measure of agreement. The agreement of the results by kappa () values is categorized as near perfect (0.81 to 1.0), substantial (0.61 to 0.8), moderate (0.41 to 0.6), fair (0.21 to 0.4), slight (0 to 0.2), or poor (Ͻ0) (4).
RESULTS
Comparison of six treponemal assays to the FTA assay. Following testing of 303 serum samples, the results of each treponema-specific assay were compared to those of the FTA assay, which was established as the gold standard method, similar to numerous prior studies (6, 11 Comparison of seven treponemal assays to a consensus of the test panel. Due to the limitations of the FTA assay as a gold standard (e.g., subjective interpretation resulting in interand intrareader variability), we also analyzed the data by comparing the results of each treponema-specific assay to a "consensus of the test panel," which was defined as at least 4 Table 2) .
Assessment of analytical specificity. All members of the cross-reactivity panel, including 28 sera from pregnant females, were negative when tested with the BioPlex syphilis IgG, TrepChek IgG, TP-PA, and Trep-Sure assays. The FTA assay yielded negative results for all members of the cross-reactivity panel, with the exception of 1 of 5 (20%) samples known to be positive for anti-Epstein-Barr virus (EBV) VCA IgG and 1 of 28 (3.6%) sera collected from pregnant females. All crossreactivity samples were negative with the ViraBlot IgG assay, with the exception of 1 of 28 (3.6%) sera collected from pregnant females, which resulted as equivocal with the ViraBlot IgG assay. The Trep-ID EIA yielded negative results for all members of the cross-reactivity panel, except for 1 of 28 (3.6%) samples from pregnant females, which was positive by this assay. Finally, all cross-reactivity samples were negative by the RPR assay, with the exception of 1 of 5 (20%) samples that was positive for anti-EBV VCA IgG (Table 3) .
Turnaround time, sample throughput, and reagent cost. The BioPlex syphilis IgG assay was estimated to yield the shortest TAT (1.75 h) for the analysis and reporting of 100 samples. In contrast, the Trep-ID assay had an estimated TAT of 5.7 h for 100 samples, using a single instrument and interpreting technologist. The BioPlex yielded the highest estimated sample throughput (514 samples) during a 9-h shift, while the Trep-ID assay was estimated to generate the lowest sample throughput (158 samples). The list price reagent cost (cost per patient) ranged from $1.73 (TP-PA) to $18.75 (Trep-ID); however, these values do not account for instrumentation or associated personnel cost (Table 4) .
DISCUSSION
Recent updates to the syphilis testing algorithm propose the use of a treponema-specific assay (e.g., EIA) for screening purposes, with positive samples being analyzed by a nontreponemal test (1) . This paradigm shift represents a reversal of a long-held practice and has generated substantial confusion among health care providers and patients, especially when results are positive by a treponemal screening assay but negative by nontreponemal tests. This discordance in test results is commonly observed in our laboratory and prompted us to evaluate and implement a second treponema-specific assay for supplemental/confirmatory purposes.
Despite our findings showing comparable performance of the 7 treponemal assays, there were samples with discordant results that became a focus for further investigation. In order to potentially resolve these discrepancies, we reviewed the results of all other treponemal tests, as well as those of the RPR and IgM assays, to determine the likelihood of past or recent infection. Among the 3 samples that were BioPlex positive, consensus of the panel ("panel" hereinafter) negative, 1 sample showed results consistent with recent infection due to positive results by 2 other treponemal tests (Trep-Sure EIA and ViraScan IgG), as well as positive IgM and RPR results (titer ϭ 16). The remaining 2 samples were negative by all other tests and were interpreted as probable false-positive BioPlex results (Table 2) .
When we compared the FTA results to the consensus of the panel, we identified 3 discordant samples, with FTA-positive, panel-negative results. One of these 3 samples was also positive by the Trep-Sure assay but negative by all other tests. The remaining 2 samples were negative by all other tests (including the RPR and IgM assays) and were interpreted as probable false-positive FTA results (Table 2) .
Among the 2 Trep-Chek discordant samples (Table 2) , 1 sample was Trep-Chek positive, panel negative. This sample was also positive by the Trep-Sure assay but was negative by all other tests. The second discordant sample (Trep-Chek negative, panel positive) showed results consistent with infection due to positive results by the 6 other treponemal assays, as well as a positive RPR assay (titer ϭ 2). We interpreted this sample as a probable false-negative Trep-Chek IgG result.
During our data analysis, we identified 6 TP-PA discordant samples. Among the 5 TP-PA-positive, panel-negative samples, 1 was also positive by the ViraBlot IgG assay but was negative by all other tests. The remaining 4 samples were negative by all other tests and were interpreted as probable false-positive TP-PA results. There was also 1 sample that was TP-PA negative, panel positive. This sample showed results consistent with recent infection due to positive results by the 6 other treponemal assays, as well as positive IgM and RPR results (titer ϭ 4), and therefore, was interpreted as a probable false-negative TP-PA result (Table 2) . Similarly, there were 6 Trep-Sure discordant samples when the results were compared to those of the panel. Among the 5 Trep-Sure-positive, panel-negative samples (Table 2) 
with past, treated infection due to positive results by the 6 other treponemal tests but negative IgM and RPR results ( Table 2) This study has several limitations. First, the serum samples were submitted without corresponding clinical data, so we were unable to correlate results to the clinical presentation or treatment history. Despite this, each sample was analyzed by 7 treponemal assays, as well as IgM and RPR assays, and this allowed for a robust characterization of the serologic status of each sample. A second limitation of our study is that a subset of the serum samples was selected based on prior results, and therefore, we could not determine the positive and negative predictive values of each test. Our laboratory typically observes a reactive rate of ϳ5% for syphilis IgG, so samples were selected to increase the number of positives in our evaluation. Third, the results from this study do not address whether screening with a treponema-specific assay is clinically or economically advantageous compared to screening by RPR assay. Past reports have suggested advantages and limitations to both strategies (8, 9) , and further studies are needed. Interestingly, among the 303 serum samples tested in our study, 97 (32.0%) were positive by FTA assay versus 94 (31.0%) by the panel and only 66 (21.8%) by RPR assay. Among the samples that were positive by FTA assay (n ϭ 97) or the panel (n ϭ 94), the results of the RPR assay were also positive in 61 (62.9% and 64.9%, respectively). These data are consistent with the results of prior studies, which have shown increased percent-positive rates when screening with a treponemal assay in comparison to the percent-positive rates with the RPR assay (2, 8) . This has important clinical implications, as treponema-specific assays may be positive in patients with either active syphilis or past, successfully treated disease. Therefore, it is often difficult to determine the significance of reactive treponemal screening results when nontreponemal tests are negative, especially in patients without a history of treatment for syphilis. This can complicate the interpretation of results and may lead to higher rates of treatment compared to screening with a nontreponemal test (2) .
In summary, our findings demonstrate comparable performance among the 7 treponema-specific assays evaluated. However, our data suggest that each method has limitations, including the potential for false-positive and false-negative results. Therefore, serum samples testing positive by a first-line treponemal assay (e.g., MFI) but negative by RPR assay should be analyzed with a second treponemal test (e.g., FTA, EIA, or WB) (1, 7) . In addition, it is important to underscore that health care providers must perform a thorough review of each patient's clinical and treatment history when interpreting the results of syphilis serology. 
